Fig. 3.

Preferred treatment option when (i) initiating treatment and (ii) following a treatment change. IST, immunosuppressive therapy. §Other treatments were chronic intravenous immunoglobulin (n = 1) in the USA and mitoxantrone (n = 1) in Italy for newly diagnosed patients and chronic intravenous immunoglobulin in the USA (n = 2) and China (n = 1) in patients with a recent therapy change. Data presented in (i) are for all newly diagnosed patients who had been initiated on any treatment at any point (N = 402). Data presented in (ii) are for all patients who had a recent therapy change and were still receiving therapy at the time of the study (N = 606)